Citius Oncology Inc. - Rasio total nilai perusahaan marang pendapatan CTOR

The EV/Sales ratio for Citius Oncology, Inc. (CTOR) demonstrates growth potential driven by biologics patents for lymphoma treatment, with the value holding around 6500.70. Future earnings are based on the results of clinical trials for targeted drugs. Cost optimization is achieved by outsourcing production to third-party facilities while maintaining research centers within the US.
CTOR (citiusonc.com): rincian analitis lan laporan miturut indikator

EV/Sales assesses the total enterprise value of the business, including debt, relative to the revenue generated. The current change in the EV/Sales ratio has reached 6500.70, reflecting market expectations for sales scaling. This metric demonstrates the efficiency of asset monetization without the influence of capital structure. The stability of this ratio confirms the maturity of the Citius Oncology (CTOR) strategy. The company's high authority in developing targeted blood cancer therapies ensures a sustainable fundamental valuation.